ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism (ULTIMA)
This study is currently recruiting participants.
Verified June 2012 by EKOS Corporation
Sponsor:
EKOS Corporation
Information provided by (Responsible Party):
EKOS Corporation
ClinicalTrials.gov Identifier:
NCT01166997
First received: July 15, 2010
Last updated: June 27, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio will be significantly reduced in the treatment arm compared to the control arm.
| Condition | Intervention | Phase |
|---|---|---|
|
Submassive Pulmonary Embolism |
Device: EkoSonic Endovascular System Drug: Unfractionated heparin |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism |
Resource links provided by NLM:
Further study details as provided by EKOS Corporation:
Primary Outcome Measures:
- Reduction of RV/LV ratio [ Time Frame: 24 hours ] [ Designated as safety issue: No ]RV/LV ratio will be measured by echocardiography at baseline. RV/LV ratio will be measured again by echocardiography at 24 hours.
| Estimated Enrollment: | 50 |
| Study Start Date: | July 2010 |
| Estimated Study Completion Date: | March 2013 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Ultrasound accelerated thrombolysis
Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose <20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
|
Device: EkoSonic Endovascular System
The EkoSonic Endovascular System will be used to deliver < 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
|
|
Active Comparator: Intravenous unfractionated heparin
Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
|
Drug: Unfractionated heparin
Intravenous unfractionated heparin used for anticoagulation treatment
|
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with acute PE symptoms < 14 days.
- Filling defect by contrast-enhanced chest CT in at least one main or proximal lower lobe pulmonary artery
- Right ventricular dysfunction confirmed by echocardiography where the RV/LV end diastolic diameter ratio is ≥ 1.0.
Exclusion Criteria:
- Age less than 18 years or greater than 80 years
- Index PE symptom duration > 14 days
- Insufficient echocardiographic image quality in the apical or subcostal four-chamber view that prohibits the measurement of the right and left ventricular end-diastolic dimensions
- Known significant bleeding risk
- Administration of thrombolytic agents, e.g., tissue plasminogen activator, streptokinase, or urokinase, within the previous 4 days
- Active bleeding
- Known bleeding diathesis
- Known coagulation disorder, platelet count < 100 000/mm3, or previous use of vitamin K antagonists with INR > 2.5
- History of any intracranial or intraspinal surgery or trauma or intracranial/intraspinal bleed
- Intracranial neoplasm, arteriovenous malformation, or aneurysm
- Recent (< 3 months) GI bleeding.
- Recent (< 3 months) internal eye surgery or hemorrhagic retinopathy; recent (< 10 days) major surgery, cataract surgery, trauma, CPR, obstetrical delivery, or other invasive procedure.
- Allergy, hypersensitivity, or thrombocytopenia from heparin, rt-PA, or iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used.
- Estimated glomerular filtration rate (eGFR) < 50 ml/min as calculated by the Cockroft formula.
- Hemodynamic collapse at presentation defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min, or drop of systolic blood pressure by at least 40 mm Hg for at least 15 min with signs of end organ hypoperfusion (cold extremities or low urinary output < 30 mL/h or mental confusion); or need for catecholamine administration to maintain adequate organ perfusion and a systolic blood pressure of > 90 mm Hg.
- Severe hypertension on repeated readings (systolic > 180 mmHg or diastolic > 105 mmHg).
- Pregnant, lactation or parturition within the previous 30 days (positive pregnancy test, women of childbearing age must be tested).
- Participating in any other investigational drug or device study.
- Life expectancy < 90 days.
- Inability to comply with study assessments (e.g. due to geographic distance).
- Previous enrollment in this study
- Any other condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.
- Known right-to-left shunt, for example from large patent foramen ovale or atrial septal defect
- Large (>10 mm) right atrial or right ventricular thrombus
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01166997
Contacts
| Contact: Nils Kucher, Prof Dr med | 42 79 82 55461 | nils.kucher@insel.ch |
Locations
| Germany | |
| Klinikum Lippe-Detmold | Recruiting |
| Detmold, Germany, 32756 | |
| Contact: Ulrich Tebbe, Prof Dr Med +49 (0) 5231 72-1181 ulrich.tebbe@uniklinikum-lippe.de | |
| Contact: Dirk Härtel, Dr dirk.haertel@uniklinikum-lippe.de | |
| Principal Investigator: Ulrich Tebbe, Prof Dr med | |
| Klinikum Dortmund gGmbH | Recruiting |
| Dortmund, Germany, 44137 | |
| Contact: Thomas Heitzer, Prof Dr med +49 (0) 231 95321760 thomas.heizter@klinikumdo.de | |
| Principal Investigator: Thomas Heitzer, Prof Dr med | |
| Universitätsklinikum Carl Gustav Carus an der TU Dresden | Recruiting |
| Dresden, Germany, 01307 | |
| Contact: Jan Beyer-Westendorf, Dr med +49 (351) 458-3659 beyer.jan@uniklinikum-dresden.de | |
| Principal Investigator: Jan Beyer-Westendorf, Dr med | |
| Universitätsklinikum der Ernst-Moritz-Arndt-Universität, | Recruiting |
| Greifswald, Germany, 17475 | |
| Contact: Klaus Empen, Dr. med +49 (3834) 86 80505 empen@uni-greifswald.de | |
| Principal Investigator: Klaus Empen, Dr med | |
| Universitätsklinikum Heidelberg | Recruiting |
| Heidelberg, Germany, 69120 | |
| Contact: Erwin Blessing, Prof Dr med +49 (6221) 56-8676 Erwin.Blessing@med.uni-heidelberg.de | |
| Contact: Arthur Filusch, Dr arthur.filusch@med.uni-heidelberg.de | |
| Principal Investigator: Erwin Blessing, Prof Dr med | |
| Klinikum der Ludwig-Maximilians-Universität (LMU) | Recruiting |
| München, Germany, 81377 | |
| Contact: Christian Kupatt, Prof.Dr.med +49 (0) 89 7095-3075 christian.kupatt@med.uni-muenchen.de | |
| Principal Investigator: Christian Kupatt, Prof Dr med | |
| Christliches Krankenhaus Quakenbrueck | Not yet recruiting |
| Quakenbrueck, Germany, 49610 | |
| Contact: Bettina Goetting, Dr. med. +49 (5431) 15-2888 b.goetting@ckq-gmbh.de | |
| Principal Investigator: Bettina Goetting, Dr. med. | |
| Helios Klinikum Siegburg | Recruiting |
| Siegburg, Germany, 53721 | |
| Contact: Peter Boekstegers, Prof Dr med +49 (2241) 18-2268 Peter.boekstegers@helios-kliniken.de | |
| Contact: Jan Horstkotte, Dr jan.horstkotte@helios-kliniken.de | |
| Principal Investigator: Peter Boekstegers, Prof Dr med | |
| SRH Zentralklinikum Suhl | Recruiting |
| Suhl, Germany, 98527 | |
| Contact: Torsten Fuss, Dr. med. +49 (0) 3681 355438 torsten.fuss@zs.srh.de | |
| Principal Investigator: Torsten Fuss, Dr. med. | |
| Marienhospital Wesel, Klinik für Innere Medizin I | Withdrawn |
| Wesel, Germany, 46483 | |
| Switzerland | |
| Inselspital Bern, Kliniken fur Kardiologie and Angiologie | Recruiting |
| Bern, Switzerland, 3010 | |
| Contact: Nils Kucher, MD 00 41 31 3220211 nils.kucher@insel.ch | |
| Contact: Mira Bartz-Batliner, Coordinator mira.bartz-batliner@insel.ch | |
| Principal Investigator: Nils Kucher, Prof Dr med | |
Sponsors and Collaborators
EKOS Corporation
Investigators
| Principal Investigator: | Nils Kucher, Prof Dr med | Inselspital Bern, Kliniken für Angiologie und Kardiologie |
More Information
No publications provided
| Responsible Party: | EKOS Corporation |
| ClinicalTrials.gov Identifier: | NCT01166997 History of Changes |
| Other Study ID Numbers: | EKOS Protocol Number 08 |
| Study First Received: | July 15, 2010 |
| Last Updated: | June 27, 2012 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices Switzerland: Swissmedic |
Keywords provided by EKOS Corporation:
|
Pulmonary embolism Pulmonary thromboembolism anticoagulation thrombolysis ultrasound accelerated thrombolysis |
Additional relevant MeSH terms:
|
Embolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Calcium heparin Heparin |
Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 19, 2013